Denosumab will play an important role in patients with solid tumours and bone metastases

Until recently, bisphosphonates, especially zoledronic acid (ZA), were considered standard treatment for prevention of skeletal related events (SREs) in patients with bone metastases. This trial compared the efficacy and safety of denosumab to ZA in the patients with advanced cancer (Excluding Breast and Prostate Cancer) or multiple myeloma (1).